620 Memorial Drive
6 articles with Syros Pharmaceuticals
Syros Pharmaceuticals today announced new preclinical data on SY-1365
Syros Announces Promising Clinical Data from Ongoing Phase 2 Trial of SY-1425 in Genomically Defined AML and MDS Patients at ASH Annual Meeting
SY-1425 in Combination with Azacitidine Shows 63% Overall Response Rate and Rapid Onset of Clinical Responses in RARA or IRF8 Biomarker-Positive Newly Diagnosed Unfit AML Patients
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the 30th Annual Piper Jaffray Healthcare Conference. Details are as follows:
Syros Announces Dose Escalation Data from Phase 1 Trial of SY-1365 Demonstrating Proof-of-Mechanism at Tolerable Doses in Patients with Advanced Solid Tumors
Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that data from the dose escalation portion of its Phase 1 trial of SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor, demonstrated proof-of-mechanism at tolerable doses in patients with advanced solid tumors.
Syros Presents New Preclinical Combination Data on SY-1365 and First Preclinical Data from Oral CDK7 Inhibitor Program at EORTC-NCI-AACR Meeting
SY-1365 Shows Synergistic Anti-Tumor Activity in Combination with Carboplatin in Preclinical Models of Ovarian Cancer.
Syros Announces Presentation of New Preclinical Data on SY-1365 in Treatment-Resistant HR-Positive Breast Cancer Cell Lines at San Antonio Breast Cancer Symposium
Syros Pharmaceuticals today announced that new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor, will be featured in a Spotlight poster discussion session at the San Antonio Breast Cancer Symposium taking place December 4-8 in San Antonio.